Plexus Corp. 10-Q Summary: Quarter Ended July 2, 2005
Business Context and Reporting Period
Plexus Corp. is an Electronic Manufacturing Services (EMS) provider offering product realization services to OEMs in wireline/networking, wireless infrastructure, medical, industrial/commercial, and defense/security/aerospace sectors. This report covers the third quarter and nine months ended July 2, 2005. The company operates 18 facilities across North America, Europe, and Asia.
Key Financial Metrics
| Metric | Q3 2005 | Q3 2004 | 9M 2005 | 9M 2004 |
|---|---|---|---|---|
| Net Sales ($ millions) | $313.7 | $274.8 | $906.7 | $767.6 |
| Gross Profit ($ millions) | $27.1 | $23.0 | $75.0 | $63.8 |
| Gross Margin | 8.7% | 8.4% | 8.3% | 8.3% |
| Operating Income (Loss) ($ millions) | $(19.8) | $(0.4) | $(20.8) | $7.8 |
| Net Income (Loss) ($ millions) | $(21.5) | $(0.8) | $(22.9) | $5.2 |
| Diluted EPS | $(0.50) | $(0.02) | $(0.53) | $0.12 |
| Cash from Operations ($ millions) | N/A | N/A | $38.5 | $(34.4) |
| Cash and Equivalents ($ millions) | $64.2 | N/A | $64.2 | $55.7 |
| Debt Outstanding ($ millions) | $0.0 | N/A | $0.0 | N/A |
Liquidity: The company holds $64.2 million in cash and cash equivalents. It has a $150 million secured revolving credit facility with no borrowings outstanding as of July 2, 2005.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% in Q3 and 18% for the nine-month period, driven by growth in wireline/networking and medical sectors.
- Restructuring and Impairment: The company recorded $27.6 million in restructuring and impairment costs in Q3 2005 (vs. $5.5 million in Q3 2004). This includes a $26.9 million goodwill impairment charge related to operations in Juarez, Mexico, and the United Kingdom.
- Profitability: Despite revenue growth, the company reported a net loss of $21.5 million in Q3 2005 compared to a loss of $0.8 million in the prior year, primarily due to the non-cash goodwill impairment.
- Customer Concentration: Concentration increased; Juniper Networks accounted for 20% of sales (up from 14% prior year) and General Electric for 12%.
Guidance, Outlook, and Risks
- Guidance: Management expects Q4 2005 sales to range between $315 million and $325 million, implying 17-18% annual growth for fiscal 2005. Comparable sales growth is anticipated for fiscal 2006.
- Subsequent Events: A significant UK medical customer announced a government investigation and postponed product installations, creating uncertainty for future demand. Additionally, new UK tax legislation may limit interest expense deductions.
- Restructuring: The company is converting its Maldon, England facility from manufacturing to a service center, anticipating further workforce reductions and costs of $0.4-$0.6 million. The Bothell, Washington facility closure is substantially complete.
- Accounting Changes: Adoption of SFAS No. 123(R) regarding stock-based compensation is required in Q1 2006, which is expected to have a significant adverse effect on reported earnings.
- Risks: Key risks include customer order volatility, supply chain shortages, foreign currency fluctuations, and the impact of new regulations (RoHS, WEEE) in the EU.
Investor Verification Checklist
- Verify the status of the significant UK medical customer under government investigation and its impact on future order books.
- Confirm the timeline and cost implications of the Maldon, England facility conversion.
- Assess the impact of the new UK Finance Act on the deductibility of intercompany interest expenses.
- Monitor the adoption of SFAS No. 123(R) in Q1 2006 and its effect on future net income.
- Review the remaining $13.6 million restructuring liability and the schedule for lease exit payments.